|
1
|
Davis AM, Bell RS and Goodwin PJ:
Prognostic factors in osteosarcoma: A critical review. J Clin
Oncol. 12:423–431. 1994.PubMed/NCBI
|
|
2
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Trieb K and Kotz R: Proteins expressed in
osteosarcoma and serum levels as prognostic factors. Int J Biochem
Cell Biol. 33:11–17. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mogi M and Kondo A: The presence of
RANKL-OPG complex in human osteosarcoma U2OS. J Immunoassay
Immunochem. 34:356–364. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Beristiain AG, Narala SR, DiGrappa MA and
Khokha R: Homotypic RANK signalling differentially regulates
proliferation, motility and cell survival in osteosarcoma and
mammary epithelial cells. J Cell Sci. 125:943–955. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rousseau J, Escriou V, Lamoureux F, Brion
R, Chesneau J, Battaglia S, Amiaud J, Scherman D, Heymann D, Rédini
F and Trichet V: Formulated siRNAs targeting Rankl prevent
osteolysis and enhance chemotherapeutic response in osteosarcoma
models. J Bone Miner Res. 26:2452–2462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee JA, Jung JS, Kim DH, Lim JS, Kim MS,
Kong CB, Song WS, Cho WH, Jeon DG, Lee SY and Koh JS: RANKL
expression is related to treatment outcome of patients with
localized, high-grade osteosarcoma. Pediatr Blood Cancer.
56:738–743. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Akiyama T, Dass CR, Shinoda Y, Kawano H,
Tanaka S and Choong PF: Systemic RANK-Fc protein therapy is
efficacious against primary osteosarcoma growth in a murine model
via activity against osteoclasts. J Pharm Pharmacol. 62:470–476.
2010.PubMed/NCBI
|
|
9
|
Mori K, Ando K, Heymann D and Rédini F:
Receptor activator of nuclear factor-kappa B ligand (RANKL)
stimulates bone-associated tumors through functional RANK expressed
on bone-associated cancer cells? Histol Histopathol. 24:235–242.
2009.PubMed/NCBI
|
|
10
|
Mori K, Berreur M, Blanchard F, Chevalier
C, Guisle-Marsollier I, Masson M, Rédini F and Heymann D: Receptor
activator of nuclear factor-kappaB ligand (RANKL) directly
modulates the gene expression profile of RANK-positive Saos-2 human
osteosarcoma cells. Oncol Rep. 18:1365–1371. 2007.PubMed/NCBI
|
|
11
|
Bago-Horvath Z, Schmid K, Rössler F,
Nagy-Bojarszky K, Funovics P and Sulzbacher I: Impact of RANK
signalling on survival and chemotherapy response in osteosarcoma.
Pathology. 46:411–415. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ennking WF, Spanier SS and Goodman MA: A
system for the surgical staging of musculoskeletal sarcoma. Clin
Orthop Relat Res. 153:106–120. 1980.PubMed/NCBI
|
|
13
|
Salzer-Kuntschik M, Brand G and Delling G:
Determination of the degree of morphological regression following
chemotherapy in malignant bone tumors. Pathologie. 4:135–141.
1983.
|
|
14
|
Trieb K, Sulzbacher I and Kubista B: Bcl-2
correlates with localization but not outcome in human osteosarcoma.
Oncol Lett. 6:559–561. 2013.PubMed/NCBI
|
|
15
|
Zhu Y, Zhou J, Ji Y and Yu B: Elevated
expression of AKT2 correlates with disease severity and poor
prognosis in human osteosarcoma. Mol Med Rep. 10:737–742.
2014.PubMed/NCBI
|
|
16
|
Wang X, Du J, Gu P, Jin R and Lin X:
Polymeric immunoglobulin receptor expression is correlated with
poor prognosis in patients with osteosarcoma. Mol Med Rep.
9:2105–2110. 2014.PubMed/NCBI
|
|
17
|
Xu SH, Yang YL, Han SM and Wu ZH:
MicroRNA-9 expression is a prognostic biomarker in patients with
osteosarcoma. World J Surg Oncol. 12:1952014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Trieb K, Lechleitner T, Lang S, Windhager
R, Kotz R and Dirnhofer S: Heat shock protein 72 expression in
osteosarcomas correlates with good response to neoadjuvant
chemotherapy. Hum Pathol. 29:1050–1055. 1998. View Article : Google Scholar : PubMed/NCBI
|
